nanoparticle therapy clinical trials
4 Startups Strip Biologics 80% With Chronic Disease Management
Investors estimate that four startups could slash biologic drug spend by 80% within five years by integrating chronic disease management programmes, potentially reshaping budgets for lupus and arthritis care. In my time covering the Square Mile, I have watched the cost pressures of biologics erode profit margins and patient access